Sano Kei, Terauchi Ryo, Fukai Kota, Ogawa Shumpei, Noro Takahiko, Tatemichi Masayuki, Nakano Tadashi
Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Department of Preventive Medicine, Tokai University School of Medicine, Isehara, 259-1193, Japan.
Clin Ophthalmol. 2024 Dec 24;18:3905-3912. doi: 10.2147/OPTH.S482883. eCollection 2024.
We evaluated the late-onset ocular hypotensive effect of ripasudil after long-term administration in real-world clinical data and investigated its associated factors in primary open-angle glaucoma (POAG).
We reviewed the clinical patients with POAG who newly started ripasudil without changes of treatment. Enrolled eyes were assigned to two groups: positive group with the late-onset effect and negative group. Eyes that show the late-onset effect 6 months after starting ripasudil were defined as positive. Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the late-onset effect.
We enrolled 74 eyes of 74 patients with POAG (age, 67.5 ± 10.9 years; mean deviation, -11.2 ± 5.9 dB) and followed them for 14.2 ± 5.0 months. Among them, 12 (16.2%) eyes were assigned to the positive group. Retinal nerve fiber layer (RNFL) thickness (73.4 ± 12.9 vs 64.0 ± 9.8 μm, = 0.04) and primary IOP (18.8 ± 4.1 vs 15.8 ± 4.3 mmHg, = 0.01) before starting ripasudil were higher in the positive group than in the negative group. The late-onset effect was associated with higher IOP (OR, 1.22; 1.01-1.48) and thicker RNFL (2.76; 1.15-6.63).
Some patients with POAG showed the late-onset IOP-lowering effect of ripasudil, and its associated factors were higher IOP and thicker RNFL. The addition of ripasudil may offer potential benefits particularly for early-stage glaucoma with thicker RNFL.
我们在真实世界临床数据中评估了长期使用ripasudil后的迟发性眼压降低效果,并研究了其在原发性开角型青光眼(POAG)中的相关因素。
我们回顾了新开始使用ripasudil且治疗方案未改变的POAG临床患者。纳入的眼睛被分为两组:有迟发性效果的阳性组和阴性组。开始使用ripasudil 6个月后显示出迟发性效果的眼睛被定义为阳性。使用逻辑回归模型计算迟发性效果的比值比(OR)和95%置信区间(CI)。
我们纳入了74例POAG患者的74只眼睛(年龄,67.5±10.9岁;平均偏差,-11.2±5.9 dB),并对他们进行了14.2±5.0个月的随访。其中,12只眼睛(16.2%)被分配到阳性组。开始使用ripasudil前,阳性组的视网膜神经纤维层(RNFL)厚度(73.4±12.9 vs 64.0±9.8μm,P = 0.04)和初始眼压(18.8±4.1 vs 15.8±4.3 mmHg,P = 0.01)高于阴性组。迟发性效果与较高的眼压(OR,1.22;1.01 - 1.48)和较厚的RNFL(2.76;1.15 - 6.63)相关。
一些POAG患者显示出ripasudil的迟发性眼压降低效果,其相关因素是较高的眼压和较厚的RNFL。ripasudil的添加可能特别为RNFL较厚的早期青光眼提供潜在益处。